Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Molecular Cancer

Research

Eithne Costello¹  Brian Lane¹  Trevor Cox¹  Joseph Tang¹  William Greenhalf¹  Robert Sutton¹  Victoria E Shaw¹  Claire Jenkinson¹  John P Neoptolemos¹  Christopher M Halloran¹ 

[1] NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospital NHS Trust, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, L69 3GA, Liverpool, UK;

关键词: Pancreatic cancer;    Biomarker;    Cytokine;    CA19-9;    IP-10;    IL-8 and PDGF;   

DOI  :  10.1186/1476-4598-13-114

 received in 2013-12-18, accepted in 2014-04-23,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundWe investigated whether combinations of serum cytokines, used with logistic disease predictor models, could facilitate the detection of pancreatic ductal adenocarcinoma (PDAC).MethodsThe serum levels of 27 cytokines were measured in 241 subjects, 127 with PDAC, 49 with chronic pancreatitis, 20 with benign biliary obstruction and 45 healthy controls. Samples were split randomly into independent training and test sets. Cytokine biomarker panels were selected by identifying the top performing cytokines in best fit logistic regression models during multiple rounds of resampling from the training dataset. Disease prediction by logistic models, built using the resulting cytokine panels, was evaluated with training and test sets and further examined using resampled performance evaluation.ResultsFor the discrimination of PDAC patients from patients with benign disease, a panel of IP-10, IL-6, PDGF plus CA19-9 offered improved diagnostic performance over CA19-9 alone in the training (AUC 0.838 vs. 0.678) and independent test set (AUC 0.884 vs. 0.798). For the discrimination of PDAC from CP, a panel of IL-8, CA19-9, IL-6 and IP-10 offered improved diagnostic performance over CA19-9 alone with the training (AUC 0.880 vs. 0.758) and test set (AUC 0.912 vs. 0.848). Finally, for the discrimination of PDAC in the presence of jaundice from benign controls with jaundice, a panel of IP-10, IL-8, IL-1b and PDGF demonstrated improvement over CA19-9 in the training (AUC 0.810 vs. 0.614) and test set (AUC 0.857 vs. 0.659).ConclusionsThese findings support the potential role for cytokine panels in the discrimination of PDAC from patients with benign pancreatic diseases and warrant additional study.

【 授权许可】

Unknown   
© Shaw et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.